NASDAQ:PLXP - PLx Pharma Stock Price, Price Target & More

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

PLx Pharma (NASDAQ:PLXP) announced its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05. The biotechnology company earned $81.46 million during the quarter. PLx Pharma had a negative return on equity of 143.33% and a negative net margin of 10.87%. View PLx Pharma's Earnings History.

3 Wall Street analysts have issued 12 month target prices for PLx Pharma's stock. Their forecasts range from $12.00 to $14.00. On average, they expect PLx Pharma's share price to reach $13.00 in the next year. View Analyst Ratings for PLx Pharma.

Some companies that are related to PLx Pharma include AcelRx Pharmaceuticals (ACRX), Adamis Pharmaceuticals (ADMP), Teligent (TLGT), Acer Therapeutics (ACER), Bellerophon Therapeutics (BLPH), Alpine Immune Sciences (ALPN), Otonomy (OTIC), ContraFect (CFRX), Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), BioDelivery Sciences International (BDSI), Genprex (GNPX), Axovant Sciences (AXON), Aptevo Therapeutics (APVO) and Chembio Diagnostics (CEMI).

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Media stories about PLXP stock have trended somewhat negative recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PLx Pharma earned a media sentiment score of -0.19 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

PLx Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Texas Treasury Safekeeping Trust Co. (0.67%) and CVI Holdings LLC (0.53%). Company insiders that own PLx Pharma stock include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Institutional Ownership Trends for PLx Pharma.

PLXP stock was bought by a variety of institutional investors in the last quarter, including Texas Treasury Safekeeping Trust Co. and CVI Holdings LLC. Company insiders that have bought PLx Pharma stock in the last two years include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Insider Buying and Selling for PLx Pharma.

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PLXP stock can currently be purchased for approximately $4.30.

PLx Pharma has a market capitalization of $37.31 million and generates $780,000.00 in revenue each year. The biotechnology company earns $-15,340,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. PLx Pharma employs 14 workers across the globe.

PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]